The abstract is read at the publisher; the summary is JClub's.
China approved satricabtagene autoleucel (satri-cel), a CAR T-cell therapy for claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.
- Why it matters: Solid tumors have been difficult targets for CAR T cells, so regulatory approval based on clinical benefit helps close a major treatment gap.
- What they did: The approval was based on a phase II trial in this patient population, assessing progression-free survival and overall survival after treatment with satricabtagene autoleucel (satri-cel).
- The result: The trial reported increased progression-free survival and overall survival, supporting use in these cancers while indicating more research is needed to improve effectiveness.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.